Literature DB >> 9368086

In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole.

D A Stevens1, B H Aristizabal.   

Abstract

Thirty-three patient fungal isolates were studied by broth macrodilution methods for susceptibility to novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and fluconazole. MICs (micrograms/ml) ranged widely, but none had lower MICs for Candida albicans or Cryptococcus neoformans than UR-9751. Fluconazole and UR-9751 had the most activity versus other Candida species. Activity was demonstrated versus endemic fungal pathogens. Aspergillus species were generally resistant, although modest activity was seen. UR-9746 and UR-9751 are active in vitro, with a potency comparable to that of fluconazole.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9368086     DOI: 10.1016/s0732-8893(97)00104-1

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  13 in total

1.  Efficacy of micafungin alone or in combination against systemic murine aspergillosis.

Authors:  Javier Capilla Luque; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Large-Scale Evaluation of In Vitro Amphotericin B, Triazole, and Echinocandin Activity against Coccidioides Species from U.S. Institutions.

Authors:  George R Thompson; Bridget M Barker; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.

Authors:  Perparim Kamberi; Raymond A Sobel; Karl V Clemons; Andreas Waldvogel; Joan M Striebel; Paul L Williams; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

4.  Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens.

Authors:  D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

Authors:  K V Clemons; M Martinez; L Calderon; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

6.  Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

7.  Efficacy of posaconazole in a murine model of central nervous system aspergillosis.

Authors:  Jackie K Imai; Gaurav Singh; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection.

Authors:  Tom M Chiller; Raymond A Sobel; Javier Capilla Luque; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center.

Authors:  David A Stevens; Richard B Moss; Cathy Hernandez; Karl V Clemons; Marife Martinez
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.